Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by PDT Partners LLC

PDT Partners LLC boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2,111.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 327,608 shares of the company's stock after buying an additional 312,794 shares during the quarter. PDT Partners LLC owned approximately 0.32% of Intellia Therapeutics worth $3,820,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. raised its position in shares of Intellia Therapeutics by 125.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock worth $1,411,000 after acquiring an additional 67,276 shares in the last quarter. Avanza Fonder AB acquired a new stake in Intellia Therapeutics during the fourth quarter worth approximately $421,000. Barclays PLC lifted its position in shares of Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after buying an additional 44,022 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock valued at $320,000 after buying an additional 1,538 shares in the last quarter. Finally, ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after buying an additional 280,946 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Truist Financial decreased their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Wedbush reiterated a "neutral" rating and issued a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a report on Friday, February 28th. Barclays decreased their price target on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Finally, Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Stock Up 2.3 %

Shares of NTLA traded up $0.20 on Friday, reaching $8.84. The stock had a trading volume of 3,461,561 shares, compared to its average volume of 2,422,444. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.18. The firm has a market capitalization of $915.67 million, a PE ratio of -1.62 and a beta of 2.33. The firm has a 50-day moving average of $8.35 and a 200 day moving average of $11.45.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.